Antibody Cosmetics Protein 
Roots Analysis
SEPTEMBER 9, 2024
Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.
Pharmaceutical Technology
MARCH 1, 2023
The drug candidate targets DNA-dependent protein kinase (DNA-PK). It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 1, 2023
The drug candidate targets DNA-dependent protein kinase (DNA-PK). It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials.
Roots Analysis
AUGUST 15, 2023
Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.
The Pharma Data
NOVEMBER 21, 2020
Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19. Hahn , M.D.
The Pharma Data
FEBRUARY 13, 2022
Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. When used to treat COVID-19 for the authorized population, the known and potential benefits of these antibodies outweigh the known and potential risks.
The Pharma Data
APRIL 18, 2022
and occur when the body’s immune system reacts to certain proteins in food. The draft guidance focuses on immunoglobulin E antibody (IgE)-mediated food allergies, which are capable of triggering anaphylaxis and are considered the most severe and immediately life-threatening food allergies. effective Jan. Federal Register.
Expert insights. Personalized for you.
40 
Let's personalize your content